BACKGROUND AND METHODS. Tamoxifen, a synthetic antiestrogen, increases disease-free and overall survival when used as adjuvant therapy for primary breast cancer. Because it is given for long periods, it is important to know whether tamoxifen affects the skeleton, particularly since it is used extensively in postmenopausal women who are at risk for osteoporosis. Using photon absorptiometry, we studied the effects of tamoxifen on the bone mineral density of the lumbar spine and radius and on biochemical measures of bone metabolism in 140 postmenopausal women with axillary-node-negative breast cancer, in a two-year randomized, double-blind, placebo-controlled trial. RESULTS. In the women given tamoxifen, the mean bone mineral density of the lumbar spine increased by 0.61 percent per year, whereas in those given placebo it decreased by 1.00 percent per year (P less than 0.001). Radial bone mineral density decreased to the same extent in both groups. In a subgroup randomly selected from each group, serum osteocalcin and alkaline phosphatase concentrations decreased significantly in women given tamoxifen (P less than 0.001 for each variable), whereas serum parathyroid hormone and 1,25-dihydroxyvitamin D concentrations did not change significantly in either group. CONCLUSIONS. In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine. Whether this favorable effect on bone mineral density is accompanied by a decrease in the risk of fractures remains to be determined.
Source Information
Department of Human Oncology, University of Wisconsin-Madison.
This article has been cited by other articles:
Brown, K.
(2009). Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis
24: 391-404
[Abstract][Full Text]
Hadji, P., Ziller, M., Kieback, D. G., Dornoff, W., Tessen, H. W., Menschik, T., Kuck, J., Melchert, F., Hasenburg, A.
(2009). Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol
20: 1203-1209
[Abstract][Full Text]
Hickey, M., Peate, M., Saunders, C.M., Friedlander, M.
(2009). Breast cancer in young women and its impact on reproductive function. Hum Reprod Update
15: 323-339
[Abstract][Full Text]
Komm, B. S.
(2008). Review Article: A New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex. Reproductive Sciences
15: 984-992
[Abstract]
Kojetin, D. J, Burris, T. P, Jensen, E. V, Khan, S. A
(2008). Implications of the binding of tamoxifen to the coactivator recognition site of the estrogen receptor. Endocr Relat Cancer
15: 851-870
[Abstract][Full Text]
Camacho, P. M., Dayal, A. S., Diaz, J. L., Nabhan, F. A., Agarwal, M., Norton, J. G., Robinson, P. A., Albain, K. S.
(2008). Prevalence of Secondary Causes of Bone Loss Among Breast Cancer Patients With Osteopenia and Osteoporosis. JCO
26: 5380-5385
[Abstract][Full Text]
Saarto, T., Vehmanen, L., Blomqvist, C., Elomaa, I.
(2008). Ten-Year Follow-Up of 3 Years of Oral Adjuvant Clodronate Therapy Shows Significant Prevention of Osteoporosis in Early-Stage Breast Cancer. JCO
26: 4289-4295
[Abstract][Full Text]
Jordan, V. C.
(2008). The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?. JCO
26: 3073-3082
[Abstract][Full Text]
Jordan, V. C.
(2008). The Rise of Raloxifene and the Fall of Invasive Breast Cancer. JNCI J Natl Cancer Inst
100: 831-833
[Full Text]
Miller, V. M., Duckles, S. P.
(2008). Vascular Actions of Estrogens: Functional Implications. Pharmacol. Rev.
60: 210-241
[Abstract][Full Text]
Hadji, P
(2008). Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer
15: 73-90
[Abstract][Full Text]
Ariazi, E. A., Leitao, A., Oprea, T. I., Chen, B., Louis, T., Bertucci, A. M., Sharma, C. G.N., Gill, S. D., Kim, H. R., Shupp, H. A., Pyle, J. R., Madrack, A., Donato, A. L., Cheng, D., Paige, J. R., Jordan, V. C.
(2007). Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics
6: 2817-2827
[Abstract][Full Text]
Jordan, V. C.
(2007). SERMs: Meeting the Promise of Multifunctional Medicines. JNCI J Natl Cancer Inst
99: 350-356
[Abstract][Full Text]
Cvoro, A., Paruthiyil, S., Jones, J. O., Tzagarakis-Foster, C., Clegg, N. J., Tatomer, D., Medina, R. T., Tagliaferri, M., Schaufele, F., Scanlan, T. S., Diamond, M. I., Cohen, I., Leitman, D. C.
(2007). Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract. Endocrinology
148: 538-547
[Abstract][Full Text]
McDonnell, D. P.
(2006). Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. FASEB J.
20: 2432-2434
[Full Text]
Chien, A. J., Goss, P. E.
(2006). Aromatase Inhibitors and Bone Health in Women With Breast Cancer. JCO
24: 5305-5312
[Full Text]
Hirbe, A., Morgan, E. A., Uluckan, O., Weilbaecher, K.
(2006). Skeletal complications of breast cancer therapies.. Clin. Cancer Res.
12: 6309s-6314s
[Abstract][Full Text]
Nijenhuis, T., van der Eerden, B. C. J., Zugel, U., Steinmeyer, A., Weinans, H., Hoenderop, J. G. J., van Leeuwen, J. P. T. M., Bindels, R. J. M.
(2006). The novel vitamin D analog ZK191784 as an intestine-specific vitamin D antagonist. FASEB J.
20: 2171-2173
[Abstract][Full Text]
Ryan, P. D., Goss, P. E.
(2006). Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer. The Oncologist
11: 718-731
[Abstract][Full Text]
Kazmin, D., Prytkova, T., Cook, C. E., Wolfinger, R., Chu, T.-M., Beratan, D., Norris, J. D., Chang, C.-y., McDonnell, D. P.
(2006). Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators. Mol. Endocrinol.
20: 1201-1217
[Abstract][Full Text]
Michaud, L. B., Goodin, S.
(2006). Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm
63: 419-430
[Abstract][Full Text]
Vehmanen, L., Elomaa, I., Blomqvist, C., Saarto, T.
(2006). Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status. JCO
24: 675-680
[Abstract][Full Text]
Colozza, M., de Azambuja, E., Cardoso, F., Bernard, C., Piccart, M. J.
(2006). Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.. The Oncologist
11: 111-125
[Abstract][Full Text]
Hall, J. M., McDonnell, D. P.
(2005). Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting. Mol. Interv.
5: 343-357
[Abstract][Full Text]
Gielen, S. C.J.P., Burger, C. W., Kuhne, L. C.M., Hanifi-Moghaddam, P., Blok, L. J.
(2005). Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin. Reproductive Sciences
12: e55-e66
[Abstract]
Banerjee, S., Smith, I. E., Folkerd, L., Iqbal, J., Barker, P., Dowsett, M., On behalf of the IMPACT trialists,
(2005). Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol
16: 1632-1638
[Abstract][Full Text]
Rau, K-M, Kang, H-Y, Cha, T-L, Miller, S A, Hung, M-C
(2005). The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer
12: 511-532
[Abstract][Full Text]
Wu, X., Ahn, E.-Y., McKenna, M. A., Yeo, H., McDonald, J. M.
(2005). Fas Binding to Calmodulin Regulates Apoptosis in Osteoclasts. J. Biol. Chem.
280: 29964-29970
[Abstract][Full Text]
Lonning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Ofjord, E. S., Paolini, J., Polli, A., Massimini, G.
(2005). Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer. JCO
23: 5126-5137
[Abstract][Full Text]
Shapiro, C. L.
(2005). Aromatase Inhibitors and Bone Loss: Risks in Perspective. JCO
23: 4847-4849
[Full Text]
Fuleihan, G. E.-H., Salamoun, M., Mourad, Y. A., Chehal, A., Salem, Z., Mahfoud, Z., Shamseddine, A.
(2005). Pamidronate in the Prevention of Chemotherapy-Induced Bone Loss in Premenopausal Women with Breast Cancer: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab.
90: 3209-3214
[Abstract][Full Text]
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., Elger, W.
(2005). Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocr. Rev.
26: 423-438
[Abstract][Full Text]
Kudachadkar, R., O'Regan, R. M.
(2005). Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer. CA Cancer J Clin
55: 145-163
[Abstract][Full Text]
Strasser-Weippl, K., Goss, P. E.
(2005). Advances in Adjuvant Hormonal Therapy for Postmenopausal Women. JCO
23: 1751-1759
[Full Text]
Perry, M. J., Gujra, S., Whitworth, T., Tobias, J. H.
(2005). Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice. Endocrinology
146: 1060-1065
[Abstract][Full Text]
Love, R. R., Hutson, P. R., Havighurst, T. C., Cleary, J. F.
(2005). Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer. Clin. Cancer Res.
11: 1500-1503
[Abstract][Full Text]
Gorodeski, G. I., Hopfer, U., Liu, C. C., Margles, E.
(2005). Estrogen Acidifies Vaginal pH by Up-Regulation of Proton Secretion via the Apical Membrane of Vaginal-Ectocervical Epithelial Cells. Endocrinology
146: 816-824
[Abstract][Full Text]
McDonnell, D. P.
(2005). The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer. Clin. Cancer Res.
11: 871s-877s
[Abstract][Full Text]
Schultz, J. R., Petz, L. N., Nardulli, A. M.
(2005). Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors {alpha} and {beta}. J. Biol. Chem.
280: 347-354
[Abstract][Full Text]
Yamamoto, Y., Shibata, J., Yonekura, K., Sato, K., Hashimoto, A., Aoyagi, Y., Wierzba, K., Yano, S., Asao, T., Buzdar, A. U., Terada, T.
(2005). TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor {alpha} and a Partial Agonist on Estrogen Receptor {beta} with Low Uterotrophic Effect. Clin. Cancer Res.
11: 315-322
[Abstract][Full Text]
Sverrisdottir, A., Fornander, T., Jacobsson, H., von Schoultz, E., Rutqvist, L.E.
(2004). Bone Mineral Density Among Premenopausal Women With Early Breast Cancer in a Randomized Trial of Adjuvant Endocrine Therapy. JCO
22: 3694-3699
[Abstract][Full Text]
Bardin, A, Boulle, N, Lazennec, G, Vignon, F, Pujol, P
(2004). Loss of ER{beta} expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer
11: 537-551
[Abstract][Full Text]
Kamal, M. A., Jusko, W. J.
(2004). Interactions of Prednisolone and Other Immunosuppressants Used in Dual Treatment of Systemic Lupus Erythematosus in Lymphocyte Proliferation Assays. J Clin Pharmacol
44: 1034-1045
[Abstract][Full Text]
Blakely, L. J., Buzdar, A., Chang, H.-Y., Frye, D., Theriault, R., Valero, V., Rivera, E., Booser, D., Kuritani, J., Tsuda, M.
(2004). A Phase I and Pharmacokinetic Study of TAS-108 in Postmenopausal Female Patients with Locally Advanced, Locally Recurrent Inoperable, or Progressive Metastatic Breast Cancer. Clin. Cancer Res.
10: 5425-5431
[Abstract][Full Text]
Smith, M. R., Fallon, M. A., Lee, H., Finkelstein, J. S.
(2004). Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab.
89: 3841-3846
[Abstract][Full Text]
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., Coates, A. S., Bajetta, E., Dodwell, D., Coleman, R. E., Fallowfield, L. J., Mickiewicz, E., Andersen, J., Lonning, P. E., Cocconi, G., Stewart, A., Stuart, N., Snowdon, C. F., Carpentieri, M., Massimini, G., Bliss, J. M., the Intergroup Exemestane Study,
(2004). A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. NEJM
350: 1081-1092
[Abstract][Full Text]
Nikander, E., Metsa-Heikkila, M., Ylikorkala, O., Tiitinen, A.
(2004). Effects of Phytoestrogens on Bone Turnover in Postmenopausal Women with a History of Breast Cancer. J. Clin. Endocrinol. Metab.
89: 1207-1212
[Abstract][Full Text]
Kian Tee, M., Rogatsky, I., Tzagarakis-Foster, C., Cvoro, A., An, J., Christy, R. J., Yamamoto, K. R., Leitman, D. C.
(2004). Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}. Mol. Biol. Cell
15: 1262-1272
[Abstract][Full Text]
Smith, C. L., O'Malley, B. W.
(2004). Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators. Endocr. Rev.
25: 45-71
[Abstract][Full Text]
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Therasse, P., Palmer, M. J., Pater, J. L.
(2003). A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. NEJM
349: 1793-1802
[Abstract][Full Text]
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., Brown, S.
(2003). American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. JCO
21: 4042-4057
[Abstract][Full Text]
Jensen, E. V., Jordan, V. C.
(2003). The Estrogen Receptor: A Model for Molecular Medicine. Clin. Cancer Res.
9: 1980-1989
[Abstract][Full Text]
Wu, L., Wu, Y., Gathings, B., Wan, M., Li, X., Grizzle, W., Liu, Z., Lu, C., Mao, Z., Cao, X.
(2003). Smad4 as a Transcription Corepressor for Estrogen Receptor alpha. J. Biol. Chem.
278: 15192-15200
[Abstract][Full Text]
Sonpavde, G.
(2003). Communicating the Value of Adjuvant Chemotherapy. JCO
21: 948-949
[Full Text]
Pearce, S. T., Liu, H., Jordan, V. C.
(2003). Modulation of Estrogen Receptor alpha Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12. J. Biol. Chem.
278: 7630-7638
[Abstract][Full Text]
Riggs, B. L., Hartmann, L. C.
(2003). Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice. NEJM
348: 618-629
[Full Text]
Hodges, L. C., Cook, J. D., Lobenhofer, E. K., Li, L., Bennett, L., Bushel, P. R., Aldaz, C. M., Afshari, C. A., Walker, C. L.
(2003). Tamoxifen Functions As a Molecular Agonist Inducing Cell Cycle-Associated Genes in Breast Cancer Cells. Mol Cancer Res
1: 300-311
[Abstract][Full Text]
Col, N. F., Goldberg, R. J., Orr, R. K., Erban, J. K., Fortin, J. M., Chlebowski, R. T.
(2002). Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. Med Decis Making
22: 386-393
[Abstract]
Cameron, L. D., Leventhal, H., Love, R. R., Patrick-Miller, L. J.
(2002). Trait Anxiety and Tamoxifen Effects on Bone Mineral Density and Sex Hormone- Binding Globulin. Psychosom. Med.
64: 612-620
[Abstract][Full Text]
Love, R. R., Duc, N. B., Allred, D. C., Binh, N. C., Dinh, N. V., Kha, N. N., Thuan, T. V., Mohsin, S. K., Roanh, L. D., Khang, H. X., Tran, T. L., Quy, T. T., Thuy, N. V., The, P. N., Cau, T. T., Tung, N. D., Huong, D. T., Quang, L. M., Hien, N. N., Thuong, L., Shen, T.-z., Xin, Y., Zhang, Q., Havighurst, T. C., Yang, Y. F., Hillner, B. E., DeMets, D. L.
(2002). Oophorectomy and Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese and Chinese Women With Operable Breast Cancer. JCO
20: 2559-2566
[Abstract][Full Text]
Khosla, S., Melton, L. J. III, Riggs, B. L.
(2002). Estrogen and the Male Skeleton. J. Clin. Endocrinol. Metab.
87: 1443-1450
[Abstract][Full Text]
Liu, H., Park, W.-C., Bentrem, D. J., McKian, K. P., Reyes, A. D. L., Loweth, J. A., Schafer, J. M., Zapf, J. W., Jordan, V. C.
(2002). Structure-Function Relationships of the Raloxifene-Estrogen Receptor-alpha Complex for Regulating Transforming Growth Factor-alpha Expression in Breast Cancer Cells. J. Biol. Chem.
277: 9189-9198
[Abstract][Full Text]
Norris, J. D., Fan, D., Sherk, A., McDonnell, D. P.
(2002). A Negative Coregulator for the Human ER. Mol. Endocrinol.
16: 459-468
[Abstract][Full Text]
McDonnell, D. P., Connor, C. E., Wijayaratne, A., Chang, C.-y., Norris, J. D.
(2002). Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators. Recent Prog Horm Res
57: 295-316
[Abstract][Full Text]
Jordan, V. C., Gapstur, S., Morrow, M.
(2001). Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease. JNCI J Natl Cancer Inst
93: 1449-1457
[Abstract][Full Text]
Fitts, J. M., Klein, R. M., Powers, C. A.
(2001). Estrogen and Tamoxifen Interplay with T3 in Male Rats: Pharmacologically Distinct Classes of Estrogen Responses Affecting Growth, Bone, and Lipid Metabolism, and Their Relation to Serum GH and IGF-I. Endocrinology
142: 4223-4235
[Abstract][Full Text]
Bhat, K. P. L., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., Pezzuto, J. M.
(2001). Estrogenic and Antiestrogenic Properties of Resveratrol in Mammary Tumor Models. Cancer Res.
61: 7456-7463
[Abstract][Full Text]
Greenberger, L. M., Annable, T., Collins, K. I., Komm, B. S., Lyttle, C. R., Miller, C. P., Satyaswaroop, P. G., Zhang, Y., Frost, P.
(2001). A New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), Inhibits the Growth of Tamoxifen-sensitive and -resistant Tumors and Is Devoid of Uterotropic Effects in Mice and Rats. Clin. Cancer Res.
7: 3166-3177
[Abstract][Full Text]
Swain, S. M.
(2001). Tamoxifen for Patients With Estrogen Receptor-Negative Breast Cancer. JCO
19: 93s-97
[Full Text]
Robertson, J. F., Nicholson, R. I., Bundred, N. J., Anderson, E., Rayter, Z., Dowsett, M., Fox, J. N., Gee, J. M. W., Webster, A., Wakeling, A. E., Morris, C., Dixon, M.
(2001). Comparison of the Short-Term Biological Effects of 7{alpha}-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17{beta}-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer. Cancer Res.
61: 6739-6746
[Abstract][Full Text]
Jordan, V. C.
(2001). Selective Estrogen Receptor Modulation: A Personal Perspective. Cancer Res.
61: 5683-5687
[Full Text]
Wade, J. P.
(2001). Rheumatology: 15. Osteoporosis. CMAJ
165: 45-50
[Full Text]
Shapiro, C. L., Recht, A.
(2001). Side Effects of Adjuvant Treatment of Breast Cancer. NEJM
344: 1997-2008
[Full Text]
Connor, C. E., Norris, J. D., Broadwater, G., Willson, T. M., Gottardis, M. M., Dewhirst, M. W., McDonnell, D. P.
(2001). Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor. Cancer Res.
61: 2917-2922
[Abstract][Full Text]
Compston, J. E.
(2001). Sex Steroids and Bone. Physiol. Rev.
81: 419-447
[Abstract][Full Text]
Nuttall, M. E., Stroup, G. B., Fisher, P. W., Nadeau, D. P., Gowen, M., Suva, L. J.
(2000). Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Am. J. Physiol. Cell Physiol.
279: C1550-C1557
[Abstract][Full Text]
Holli, K., Valavaara, R., Blanco, G., Kataja, V., Hietanen, P., Flander, M., Pukkala, E., Joensuu, H.
(2000). Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer. JCO
18: 3487-3494
[Abstract][Full Text]
Osborne, C. K., Fuqua, S. A. W.
(2000). Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use. JCO
18: 3172-3186
[Abstract][Full Text]
ARIS, R. M., LESTER, G. E., RENNER, J. B., WINDERS, A., DENENE BLACKWOOD, A., LARK, R. K., ONTJES, D. A.
(2000). Efficacy of Pamidronate for Osteoporosis in Patients with Cystic Fibrosis following Lung Transplantation. Am. J. Respir. Crit. Care Med.
162: 941-946
[Abstract][Full Text]
Buzdar, A. U.
(2000). Tamoxifen's Clinical Applications: Old and New. Arch Fam Med
9: 906-912
[Abstract][Full Text]
Rodan, G. A., Martin, T. J.
(2000). Therapeutic Approaches to Bone Diseases. Science
289: 1508-1514
[Abstract][Full Text]
Dickson, R. B., Stancel, G. M.
(2000). Chapter 8: Estrogen Receptor-Mediated Processes in Normal and Cancer Cells. J Natl Cancer Inst Monogr
2000: 135-145
[Abstract][Full Text]
Herrington, D. M., Pusser, B. E., Riley, W. A., Thuren, T. Y., Brosnihan, K. B., Brinton, E. A., MacLean, D. B.
(2000). Cardiovascular Effects of Droloxifene, a New Selective Estrogen Receptor Modulator, in Healthy Postmenopausal Women. Arterioscler. Thromb. Vasc. Bio.
20: 1606-1612
[Abstract][Full Text]
Pfeilschifter, J., Diel, I. J.
(2000). Osteoporosis Due to Cancer Treatment: Pathogenesis and Management. JCO
18: 1570-1593
[Abstract][Full Text]
Qu, Q., Zheng, H., Dahllund, J., Laine, A., Cockcroft, N., Peng, Z., Koskinen, M., Hemminki, K., Kangas, L., Vaananen, K., Harkonen, P.
(2000). Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats. Endocrinology
141: 809-820
[Abstract][Full Text]
louffe, L. Jr.
(2000). Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice. Reproductive Sciences
7: S38-S46
[Abstract]
MacGregor Schafer, J. I., Liu, H., Tonetti, D. A., Jordan, V. C.
(1999). The Interaction of Raloxifene and the Active Metabolite of the Antiestrogen EM-800 (SC 5705) with the Human Estrogen Receptor. Cancer Res.
59: 4308-4313
[Abstract][Full Text]
Jordan, V C., Morrow, M
(1999). Raloxifene as a multifunctional medicine?. BMJ
319: 331-332
[Full Text]
Suh-Burgmann, E. J., Goodman, A.
(1999). Surveillance for Endometrial Cancer in Women Receiving Tamoxifen. ANN INTERN MED
131: 127-135
[Abstract][Full Text]
Love, R. R., Olsen, M. R., Havighurst, T. C.
(1999). Delayed Adjuvant Tamoxifen in Postmenopausal Women With Axillary Node-Negative Breast Cancer: Mortality Over 10 Years. JNCI J Natl Cancer Inst
91: 1167-1168
[Full Text]
Chen, Y., Schindler, M., Simon, S. M.
(1999). A Mechanism for Tamoxifen-mediated Inhibition of Acidification. J. Biol. Chem.
274: 18364-18373
[Abstract][Full Text]
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., Lippman, M. E., Black, D., Glusman, J. E., Costa, A., Jordan, V. C.
(1999). The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial. JAMA
281: 2189-2197
[Abstract][Full Text]
Jordan, V. C., Morrow, M.
(1999). Tamoxifen, Raloxifene, and the Prevention of Breast Cancer. Endocr. Rev.
20: 253-278
[Abstract][Full Text]
Chlebowski, R. T., Collyar, D. E., Somerfield, M. R., Pfister, D. G.
(1999). American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. JCO
17: 1939-1939
[Abstract][Full Text]
Previous
